Wells Fargo’s Nuvectis Pharma NVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCT
Wells Fargo's NVCT Position: Q3 2026 in Review
Wells Fargo reduced its Nuvectis Pharma (NVCT) stake by 59% in Q3 2026, selling an estimated $195K and leaving 6,353 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4956.
Wells Fargo first reported a position in NVCT in Q1 2022 and has held it in 15 quarters since. The position peaked at $287K in Q2 2026. 94 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.
- Wells Fargo held 6,353 shares of Nuvectis Pharma worth $134K as of Q3 2026.
- Wells Fargo sold 9,241 Nuvectis Pharma shares in Q3 2026, an estimated $195K.
- Nuvectis Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #4956 holding.
- Wells Fargo first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 15 quarters since.
- Wells Fargo's Nuvectis Pharma position peaked at $287K in Q2 2026.
- 94 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.